Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.79 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.55 |
| ▸ | FAP | Q12884 | 1/20 | 0.55 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928203 | 0.91 | DPP4 (0.78) | DPP4DPP8DPP9 | |
| SCHEMBL465003 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP9FAP | |
| SCHEMBL3938071 | 0.88 | DPP4 (0.62) | DPP4DPP8DPP9PREP | |
| Hydrochloric Acid SCHEMBL5207169 | 0.88 | DPP4 (0.98) | DPP4DPP8DPP9FAP | |
| SCHEMBL3928213 | 0.81 | DPP4 (0.65) | DPP4DPP8DPP9 | |
| SCHEMBL3934856 | 0.80 | DPP4 (0.66) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5207185 | 0.80 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL6166027 | 0.80 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| SCHEMBL3937891 | 0.80 | DPP4 (0.57) | DPP4DPP8DPP9PREP | |
| SCHEMBL3940074 | 0.79 | DPP4 (0.65) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560569-B2 | (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2009-07-14 | — | — | US | disclosed |
| US-7560569-B2 | (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070265320-A1 | Bicycloamide Derivative | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265320-A1 | Bicycloamide Derivative | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1717225-A1 | BICYCLIC AMIDE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265320-A1 | Bicycloamide Derivative | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 5/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.